Daniel O'Day, Gilead CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)

Daniel O’Day snatch­es an­oth­er I/O com­pa­ny, buy­ing half of a pi­o­neer­ing can­cer drug dis­cov­er­er's biotech

Gilead CEO Daniel O’Day has nabbed an­oth­er im­muno-on­col­o­gy part­ner in his quest to re­make the biotech’s can­cer di­vi­sion, ink­ing an up-to $1.5 bil­lion deal with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.